Moderna 2Q Revenues: $241 million (-30%) 2Q Loss: $1.3 billion (loss of $1.4B 2Q23) Comments: Decline in revenues is attributable to decreased sales of the Company’s COVID-19 vaccine. The company reported $184 million in Spikevax (COVID-19 vaccine) sales in the quarter, down 37%, which includes $162 million of U.S. sales and $22 million of international sales.   Cost of sales in the quarter was $115 million, which included third-party royalties of $10 million, unutilized manufacturing...